MedTrace Logo

Study to Assess the Efficacy and Safety of GF-001001-00 Cream in Secondarily-Infected Traumatic Lesions

NCT01005771 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2010-06-09

No results posted yet for this study

Summary

This is a double-blind, randomized, placebo-controlled, parallel-group, dose-finding study.

Conditions

  • Secondarily Infected Traumatic Lesions

Interventions

DRUG

GF-001001-00

GF-001001-00 2%, 1% and 0.25% twice daily for 7 days

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

  • Ferrer Internacional S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01005771 on ClinicalTrials.gov